Ocuphire Pharma Hits New 52-Week High of $4.49, Up 150%

Ocuphire Pharma, Inc. has reached a significant milestone by hitting a new 52-week high of USD 4.49 on March 3, 2026. This achievement marks a remarkable 150% increase in the stock's performance over the past year, significantly outpacing the S&P 500, which has seen a gain of 17.36% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology industry, Ocuphire Pharma has a market capitalization of USD 234 million. Despite its recent stock performance, the company remains in a loss-making position, with a negative return on equity of -577.66%. The stock's price-to-book ratio stands at 39.18, indicating a premium valuation relative to its book value. Investors may note that the stock's 52-week low was recorded at USD 0.65, highlighting the substantial growth it has experienced over the past year. This upward trend reflects the company's evolving market position within the competitive landscape of the pharmaceuticals sector.